Trials / Completed
CompletedNCT02282371
Cetuximab + BYL719 + IMRT (Intensity-Modulated Radiation Therapy) in Stage III/IVB Head and Neck Squamous Cell Cancer (HNSCC)
A Phase Ib Study of Cetuximab + BYL719 + IMRT (Intensity-Modulated Radiation Therapy) in Stage III/IVB Head and Neck Squamous Cell Cancer (HNSCC)
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 16 (estimated)
- Sponsor
- Memorial Sloan Kettering Cancer Center · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a phase 1b study, which means that the purpose of the study is to establish the maximum dose of a pill drug called BYL719, when given with a standard treatment for patients with head and neck squamous cell cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Cetuximab | |
| DRUG | BYL719 | |
| RADIATION | IMRT (Intensity-Modulated Radiation Therapy) |
Timeline
- Start date
- 2014-10-30
- Primary completion
- 2021-10-22
- Completion
- 2021-10-22
- First posted
- 2014-11-04
- Last updated
- 2021-10-26
Locations
6 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02282371. Inclusion in this directory is not an endorsement.